Worldwide: Why Combatting Cyber-Crime Is Critical For Life Science Companies

Biotech and pharmaceutical firms hold vast amounts of valuable data and information making them prime targets for cyber-attacks - so how are they protecting themselves?

In the American political thriller series, Homeland, a vice presidential candidate's pacemaker was attacked by offshore terrorists, inducing a heart attack that resulted in his untimely death. In the real world, when Dick Cheney was serving as the 46th vice president of the United States between 2001 and 2009, he famously deactivated the connectivity on his pacemaker so as to prevent anything similar from taking place.

The threat to medical devices may seem like the stuff of science fiction, but in the US, healthcare is now the largest target of cyber security attacks, reportedly at greater risk than manufacturing and banking1. According to experts, the value of stolen personal health information is ten to twenty times greater than the value of a stolen credit card number.

Valuable data

Life science companies hold vast amounts of critically important data and information. Obvious categories include data arising from the development and testing of pharmaceutical products, including clinical trial data, while the rise of biologic drugs has also brought with it valuable manufacturing know-how for these complex molecules.

The sophisticated nature of medical devices and their connectivity raises additional risks. Add in commercially sensitive information about products and their pricing and promotion, and it's no surprise that the sector finds itself the target of cyber-attacks.

Josh Hanet is a senior associate at Gowling WLG, based in Toronto, with a practice focused on medical defence law. He says healthcare cyber security is becoming a significant area of concern for medical device manufacturers and regulators tasked with protecting the public.

"So far, most of the examples in Canada and the US have been ransomware attacks, where hospital networks are attacked and a bitcoin ransom is demanded. There is a potential loss of data, and a risk that hackers have gained access to potentially significant personal health information."

Cyber-attacks as a global issue

In Europe and elsewhere, cyber-attacks are increasing thanks to the growing volume of electronic data and the rising use of electronic storage to keep data. Adding to the problem is the sophistication of cyber criminals.

Helen Davenport is a director based in Gowling WLG's London and Birmingham offices, specialising in technology-related commercial disputes, including cyber-crime and data breaches. She says: "In life sciences, there is an employee threat, where insiders may want to make use of information that they have access to, whether it is intellectual property or personal data.

"Another potential motivation is around sabotage and public profile, where there are people with grudges against pharma companies who want to cause those companies harm by disrupting their businesses and generating bad press."

Key cyber security threats

Patrick Duxbury, partner and head of life sciences with Gowling WLG in the UK, says pharma and biotech companies are concerned about cyber security threats in three key areas:

  • Data relating to clinical trials, and particularly patient data generated during clinical trials. This data is incredibly sensitive at both the patient level and at a commercial level.
  • Corporate know-how and confidential information relating to the manufacture of biologic drugs.
  • Day-to-day commercially sensitive information regarding drug pricing and promotion - a hot topic given the pressures on healthcare budgets around the world.

Duxbury says: "The explosion of large molecule drugs in the last 20 years has created new categories of very valuable information. These drugs are very difficult to make which means companies are very keen to protect their intellectual property and trade secrets. If that information is hacked, or becomes public, that would be incredibly damaging from a commercial point of view. The increasing value of trade secrets has been recognised in both the US and Europe with major legislative changes coming into force this year to enhance the statutory protection available to prevent misuse."

He adds: "Companies see themselves at risk of people hacking into their systems and stealing their know-how, and there has been a huge spike in cyber-attack attempts being made on pharmaceutical systems."

Regulators and cyber security

Regulators have a significant role to play in protecting the public from the impact of cyber security breaches. Both the American Food and Drug Administration (FDA) and European lawmakers have made regular calls for companies to tighten their systems.

The FDA has taken the lead recently in enacting legislation to address manufacturers who fail to properly prevent or rectify a cyber security risk to medical devices.  Failure to comply can now see devices disapproved, recalled, or face regulatory or legal action.

In January 2016, the FDA published draft guidance for the post-market management of cyber security in medical devices, emphasising the need to keep on top of the threat from hackers even after devices have been deployed. The post-market considerations that are critical to the FDA include:

  • Monitoring cyber security information sources for identification and detection of cyber security vulnerabilities and risks;
  • Understanding, assessing and detecting presence and impact of vulnerabilities;
  • Establishing and communicating processes for vulnerability intake and handling;
  • Defining essential clinical performance to develop programs that protect, respond and recover from the cyber security risk;
  • Adopting a coordinated vulnerability disclosure policy and practice; and
  • Deploying mitigations that address cyber security risk early and prior to exploitation.

It has also called for more collaboration between all the various stakeholders in the industry - including the IT community, manufacturers, and clinical users - to combat cyber-crime.

Hanet says: "Many of the regulators around the world are quite reactive, but the FDA is proactive, so we advise clients to look to what the FDA is doing, because where it leads, others often follow. We are seeing obligations now not just when developing devices, but also once they have hit the market. Just like the iPhone gets constantly updated as new threats emerge, now medical devices that have been deployed need to be considered in a similar way."

Information risk management

In the UK, life sciences businesses should be aware of the guidance available that deals with information risk management. For example, the government's information risk management regime puts forward 10 Steps to Cyber Security2 .

The government advises boards to establish an effective governance structure, maintain board engagement with cyber risk, and produce supporting information risk management policies.

"A lot of the guidance is around personnel, training, understanding the threat and having a comprehensive strategy in place to deal with it," says Davenport. "The threat is becoming ever-more sophisticated particularly when it comes to assets such as high-value know-how and clinical data, but equally the statistics show that many incidents involve either insider threats, or employee failure.

"My advice is to start at a fairly basic level with things like user education, network security and mobile working policies, and then develop a strategy to cover more sophisticated threats if necessary, to ensure the crown jewels of your business are protected."

Fragmented legislative framework

The contributions of the FDA and the UK government form just a small part of a legislative framework that is very fragmented, both in terms of laws and standards. An example is ISO 270013, an information security management standard published in October 2005 by the International Organisation for Standardisation.

This standard aims to bring information security under explicit management control so that organisations that have signed up can be formally audited to ensure they are compliant with the standards set. Meanwhile, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has also issued draft guidance over medical devices this year to take into account recent developments in apps.

At the European level, the Network and Information Security Directive4, otherwise known as the Cyber Security Directive, entered into force in August 2016, and member states now have 21 months to adopt its rules into national legislation.

Duxbury says: "Cyber security is very much a cross-border issue and this industry is about as international as you can get. There have been attempts across the globe to try to achieve standardisation of approach internationally, but for now companies are faced with a patchwork of legislation, regulations and guidance."

Monitoring the cyber threat

Industry will need to commit more resources to managing cyber risk as the threat continues to evolve. Three large US health insurance firms - Anthem, Premera Blue Cross and UCLA Health - have recently suffered headline-grabbing cyber-attacks concerning patient data.

Indeed, IBM research5 says 100 million medical records were compromised globally in 2015 alone. During the most recent Olympics, the World Anti-Doping Agency said Russian hackers broke into its network and released personal medical records of several top international athletes.

When it comes to the critical area of intellectual property, a PwC survey6 recently found theft of intellectual property (IP) in cyber-attacks on life sciences and pharma companies skyrocketed 176% in 2015, with many stories of hackers selling IP from life sciences firms.

"You mention cyber security and everybody's ears perk up," says Hanet. "It is on their radar, but can become a black hole as you can't possibly be on top of every threat. As technology evolves, so do the threats, often at a pace that is faster than companies can keep track of. From a regulatory perspective, companies are trying to keep ahead of the curve, and from a legal point of view, there's a concern that you are only ever one attack away from significant liability."

For now, best practice centres on the continuous monitoring of the threat, assessing and detecting vulnerability, establishing processes to address weaknesses, adopting disclosure policies, and developing and deploying mitigations when necessary.

For medical devices, the post-market management of risks is becoming as important as the pre-market - particularly if vice presidential health scares are to remain only in the realm of TV dramas.








The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
7 Nov 2019, Seminar, Birmingham, UK

Providing content specifically tailored to the needs of GCs and Heads of Legal working in government organisations and their affiliates.

14 Nov 2019, Seminar, London, UK

Providing content specifically tailored to the needs of GCs and Heads of Legal working in government organisations and their affiliates.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions